Efficacy and safety of a transaortic approach to midventricular and apical septal myectomy
The Journal of Thoracic and Cardiovascular Surgery · 2024
DOI: 10.1016/j.jtcvs.2024.04.016 ↗Kurz gefasst
Video/Audio in der Zeitschrift The Journal of Thoracic and Cardiovascular Surgery, 2024. Verfasst von Jean-Luc A Maigrot und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, Ohio. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic, Cardiac Surgical Procedures, Heart Septum. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
OBJECTIVE: The study objective was to evaluate the safety and efficacy of a transaortic approach to midventricular and apical septal myectomy in patients with hypertrophic cardiomyopathy with left ventricular outflow tract or midventricular obstruction. METHODS: From January 2018 to August 2023, 940 patients underwent transaortic septal myectomy at the Cleveland Clinic, of whom 682 (73%) had midventricular or apical resection. Patients who underwent isolated basal myectomies were excluded. Templated operative reports designated septal regions resected as basal (opposition to mitral valve up to the leaflet tips), midventricular (leaflet tips to just beyond the papillary muscle heads), and apical (apical third of the ventricle). Myocardial resection specimen weights, intraventricular gradients, and clinical outcomes were assessed. RESULTS: Of the 682 patients, 582 (85%) had basal plus midventricular resection and 78 (11%) had basal, midventricular, and apical resection. Mean preoperative intraventricular gradient was 102 ± 41 mm Hg. Median resection weight was 10 g (15th, 85th percentiles: 7, 15), and mean postoperative intraventricular gradient was 16 ± 10 mm Hg, with 625 (96%) patients achieving gradients 36 mm Hg or less. There were no iatrogenic mitral or aortic valve injuries. Permanent pacemaker placement was required in 38 patients (5.6%), of whom 8 (1.2%) had normal preoperative conduction. Operative mortality occurred in 1 patient (0.1%) after an intraoperative ventricular septal defect. CONCLUSIONS: Most patients undergoing septal myectomy for relief of obstruction required resection beyond the basal septum. With specialized instrumentation, detailed imaging and knowledge of variable septal anatomy, resecting midventricular and apical septal muscle can be safely and effectively achieved through a transaortic approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, Ohio.
- Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio.
- Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, Ohio; Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio.
- Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, Ohio. Electronic address: smedirn@ccf.org.
Zitieren
APA
Maigrot, J. A., Weiss, A. J., Steely, A. M., Firth, A., Moros, D., Blackstone, E. H., & Smedira, N. G. (2024). Efficacy and safety of a transaortic approach to midventricular and apical septal myectomy. The Journal of Thoracic and Cardiovascular Surgery. https://doi.org/10.1016/j.jtcvs.2024.04.016
Vancouver
Maigrot JA, Weiss AJ, Steely AM, Firth A, Moros D, Blackstone EH, et al. Efficacy and safety of a transaortic approach to midventricular and apical septal myectomy. The Journal of Thoracic and Cardiovascular Surgery. 2024. doi:10.1016/j.jtcvs.2024.04.016
BibTeX
@article{Maigrot2024,
author = {Maigrot, Jean-Luc A and Weiss, Aaron J and Steely, Andrea M and Firth, Austin and Moros, David and Blackstone, Eugene H and Smedira, Nicholas G},
title = {Efficacy and safety of a transaortic approach to midventricular and apical septal myectomy},
journal = {The Journal of Thoracic and Cardiovascular Surgery},
year = {2024},
doi = {10.1016/j.jtcvs.2024.04.016}
}
EUVIMED